Harrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Harrow, Inc. (NASDAQ:HROW) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $68.50.

A number of equities analysts have recently weighed in on the company. Lake Street Capital upped their target price on Harrow from $42.00 to $70.00 and gave the company a “buy” rating in a report on Monday, September 29th. B. Riley reiterated a “buy” rating and issued a $74.00 price objective (up previously from $70.00) on shares of Harrow in a research note on Wednesday, October 1st. Craig Hallum boosted their price target on shares of Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a report on Tuesday, September 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a report on Wednesday, October 8th. Finally, BTIG Research restated a “buy” rating and issued a $63.00 target price on shares of Harrow in a research note on Wednesday, September 24th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HROW. Teacher Retirement System of Texas boosted its holdings in Harrow by 4.1% in the second quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock worth $259,000 after purchasing an additional 332 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after acquiring an additional 341 shares in the last quarter. Pale Fire Capital SE boosted its stake in shares of Harrow by 6.8% during the 2nd quarter. Pale Fire Capital SE now owns 8,683 shares of the company’s stock worth $265,000 after acquiring an additional 550 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock valued at $483,000 after acquiring an additional 790 shares during the last quarter. Finally, Great Lakes Advisors LLC lifted its holdings in Harrow by 4.0% in the 3rd quarter. Great Lakes Advisors LLC now owns 26,963 shares of the company’s stock worth $1,299,000 after purchasing an additional 1,035 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

Harrow stock opened at $33.93 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The company has a market cap of $1.26 billion, a P/E ratio of -135.72 and a beta of 0.19. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $54.19. The firm’s 50 day simple moving average is $40.74 and its 200-day simple moving average is $34.61.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $0.03 earnings per share for the quarter. The firm had revenue of $22.12 million for the quarter. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its Q2 2023 guidance at EPS. As a group, equities research analysts predict that Harrow will post -0.53 EPS for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.